Sustained Remission after Rituximab-containing Chemotherapy for Intravascular Large B-cell Lymphoma

Shimada, Kazuyuki; Kosugi, Hiroshi; Narimatsu, Hiroto; Shimada, Satoko; Suzuki, Tatsuya; Ito, Masafumi; Kinoshita, Tomohiro; Mori, Naoyoshi; Naoe, Tomoki

doi:10.3960/jslrt.48.25

Cited by 14 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data shown in Tables 1 and 2 indicate that the distribution of patients between the group that received rituximab during the first course and the group that received the drug during the second or later courses was equivalent [1,3,14-35]. The chemotherapy regimens employed comprised CHOP or modified CHOP.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature

et al. 2013

View full text Add to dashboard Cite

IntroductionIntravascular large B-cell lymphoma is a rare aggressive disseminated disease characterized by the presence of lymphoma cells in small vessels without lymphadenopathy. Rituximab, a novel monoclonal antibody against the CD20 B-cell antigen, has been reported to be effective in treating intravascular large B-cell lymphoma. However, adverse events have been reported in association with rituximab infusion.Case presentationWe report the case of a 54-year-old Japanese man diagnosed with Asian variant intravascular large B-cell lymphoma who died within five hours of the initiation of a first course of chemotherapy including rituximab. Autopsy results suggested that the patient died of severe systemic inflammatory response syndrome. A literature review revealed that rituximab administered during the second course of chemotherapy (instead of during the first course) appears to reduce the incidence of infusion reactions (from 48% to 15%) without altering the frequency of complete remission outcomes.ConclusionsOur data indicate that the incidence of adverse reactions to rituximab can be markedly decreased if the tumor load is first reduced with an initial course of chemotherapy excluding rituximab. Future prospective studies of the timing of rituximab administration are warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal large B-cell lymphoma characterized by the proliferation of lymphoma cells within the lumina of small blood vessels and capillaries [1]. There is currently no standard therapeutic strategy for IVLBCL.…”

Section: Introductionmentioning

confidence: 99%

Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature

et al. 2013

View full text Add to dashboard Cite

show abstract

“…antibody rituximab (R-CHOP) is the most commonly used regimen to improve the outcome of IVLBCL [24]. Unfortunately, our patient died before treatment could be administered because of rapid disease progression.…”

Section: Case Presentationmentioning

confidence: 97%

EBV-positive intravascular large B-cell lymphoma of the liver: a case report and literature review

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Intravascular large B-cell lymphoma (IVLBCL) is an extremely rare subtype of diffuse large B-cell lymphoma that most commonly involves the central nervous system, skin, and bone marrow. To our knowledge, Epstein-Barr virus (EBV)-positive IVLBCL in the liver has never been reported in the literature. Case presentation We report a case of a 65-year-old Chinese man with complaint of fever for 18 days. No obvious abnormality was found by physical examination. Laboratory findings were notable for anemia, thrombocytopenia, and elevated level of serum lactate dehydrogenase. Imaging studies showed a slightly lower density lesion in the liver with high fluorodeoxyglucose uptake. Percutaneous liver biopsy revealed clustering of large atypical lymphocytes within the hepatic sinusoids. Immunohistochemically, these lymphoma cells were positive for CD20, PAX-5, MUM-1, BCL-6 and CD5, but negative for CD3 and CD10. Besides, Epstein-Barr virus-encoded RNA was detected in tumor cells by in situ hybridization. BCL-2 , BCL-6 and MYC genes were intact tested by fluorescence in situ hybridization analysis. The patient was diagnosed as IVLBCL and died after 1 month of hospitalization without receiving immunochemotherapy. Conclusions IVLBCL of the liver is a highly rare lymphoma with nonspecific manifestations and dismal prognosis. Full recognition of its clinicopathological features will help to better diagnose this disease.

show abstract

“…IVLBCL usually shows an aggressive clinical course with a poor prognosis. Speci cally, a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone with the recombinant anti-CD20 antibody rituximab (R-CHOP) is the most commonly used regimen to improve the outcome of IVLBCL [25]. Unfortunately, our patient died before treatment could be administered because of rapid disease progression.…”

Section: Case Presentationmentioning

confidence: 98%

EBV-positive intravascular large B-cell lymphoma of the liver: a case report and literature review

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Intravascular large B-cell lymphoma (IVLBCL) is an extremely rare subtype of diffuse large B-cell lymphoma that most commonly involves the central nervous system, skin, and bone marrow. To our knowledge, Epstein-Barr virus (EBV)-positive IVLBCL in the liver has never been reported in the literature. Case presentation We report a case of a 65-year-old Chinese man with complaint of fever for 18 days. No obvious abnormality was found by physical examination. Laboratory findings were notable for anemia, thrombocytopenia, and elevated level of serum lactate dehydrogenase. Bone marrow on smear, biopsy, and flow cytometry revealed no lymphoma. Imaging studies showed a slightly lower density lesion in the liver with high fluorodeoxyglucose uptake and hepatosplenomegaly. Percutaneous liver biopsy revealed clustering of large atypical lymphocytes within the hepatic sinusoids. Immunohistochemically, these lymphoma cells were positive for CD20, PAX-5, MUM-1, BCL-6 and CD5, but negative for CD3 and CD10. Besides, Epstein-Barr virus-encoded RNA was detected in tumor cells by in situ hybridization. BCL-2 , BCL-6 and MYC genes were intact tested by fluorescence in situ hybridization analysis. The patient was diagnosed as IVLBCL and died after 1 month of hospitalization without receiving immunochemotherapy. Conclusions IVLBCL of the liver is a highly rare lymphoma with nonspecific manifestations and dismal prognosis. Full recognition of its clinicopathological features will help to better diagnose this disease.

show abstract

Sustained Remission after Rituximab-containing Chemotherapy for Intravascular Large B-cell Lymphoma

Cited by 14 publications

References 23 publications

Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature

Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature

EBV-positive intravascular large B-cell lymphoma of the liver: a case report and literature review

EBV-positive intravascular large B-cell lymphoma of the liver: a case report and literature review

Contact Info

Product

Resources

About